858 Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.8five8tx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1
Recruiting
- Conditions
- Prostate CancerCastrate Resistant Prostate CancerBRCA MutationEndometrial CancerColorectal CancerGastric CancerAdvanced or Metastatic Solid TumorsOvarian CancerBRCA2 MutationBRCA1 Mutation
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- 858 Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06395519
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
News
No news found